DCC recommends SLAs to submit Adverse Drug Reaction

Beyond Adverse Drug Reaction (ADR) reports submission, SLAs are urged to direct manufacturers to contribute to this vital data collection.

The Health Master

November 29, 2023

130

Table of Contents

Last Updated on September 30, 2024 by The Health Master

Adverse Drug Reaction

In the dynamic landscape of healthcare, ensuring the safety and quality of medical devices is paramount. One significant initiative in this regard is the Materiovigilance Programme of India (MvPI) and Adverse Drug Reaction (ADR), a comprehensive program launched in 2015 by the Ministry of Health and Family Welfare (MoHFW).

Follow us on WhtasApp Channel

This article delves into the recent advisory from the Drugs Consultative Committee (DCC), emphasizing the active participation of State Licensing Authorities (SLAs) in the MvPI.

DCC’s Advisory on ADR Reports Submission

In its 62nd meeting, the DCC highlighted the need for SLAs across the country to actively engage in the MvPI and submit Adverse Drug Reaction (ADR) reports for Class A and B medical devices to the Indian Pharmacopoeia Commission (IPC).

This advisory underlines the critical role that SLAs play in the success of the Materiovigilance Program.

Role of State Licensing Authorities (SLAs)

The involvement of SLAs is pivotal in achieving the objectives of the MvPI.

Beyond Adverse Drug Reaction (ADR) reports submission, SLAs are urged to direct manufacturers to contribute to this vital data collection.

The MvPI aims not only to promote but also to facilitate adverse event reporting of medical devices, fostering a culture of safety and accountability.

Click for more on Adverse Drug Reaction (ADR)

Proposal from IPC, Ghaziabad

The IPC, serving as the National Coordination Centre (NCC) for MvPI, has proposed that the active participation of State Regulatory Authorities is crucial for the program’s success.

This proposal underscores the collaborative nature required to address the multifaceted challenges in the realm of medical device safety.

MvPI Objectives and Medical Devices Regulation (MDR) Rule 2017

The MvPI aligns with the Medical Devices Regulation (MDR) Rule 2017, which mandates comprehensive Post Marketing Surveillance data.

This includes vigilance reporting procedures and data collected by manufacturers, detailing complaints received and the corresponding corrective and preventive actions taken.

IPC’s Focus on Patient Safety

The IPC emphasizes that the MvPI primarily focuses on ensuring patient safety and enhancing the overall quality of medical devices.

The active involvement of State Regulatory Authorities is deemed crucial in achieving these objectives effectively.

Enhancing Adverse Event Reporting

Accurate and comprehensive adverse event reporting is imperative in the healthcare landscape.

The MvPI, with SLAs actively participating, aims to enhance the accuracy of reporting, ensuring timely intervention and corrective actions to safeguard patient well-being.

State Regulatory Authorities’ Pivotal Role

Beyond data submission, State Regulatory Authorities are identified as key players in promoting awareness about the MvPI.

Their role extends to educating healthcare professionals, manufacturers, and consumers across states, fostering a collective responsibility for patient safety.

DCC’s Meeting Conclusion

The conclusive remarks from the DCC meeting emphasize the collective responsibility of all States/UTs SLAs to submit Adverse Drug Reaction (ADR) reports of materiovigilance to IPC for Class A & B medical devices.

Simultaneously, all manufacturers are urged to be directed by SLAs to submit Adverse Drug Reaction (ADR) reports, reinforcing a unified commitment to medical device safety.

Click for more articles on Medical Devices

Background of Materiovigilance Programme

Initiated in response to alarming cases of malfunctioning medical devices causing harm to patients, the Materiovigilance Programme underscores the importance of proactive safety measures in the healthcare sector.

MvPI’s Impact on Patient Safety

Beyond addressing specific incidents, the Materiovigilance Programme plays a crucial role in reducing the likelihood of recurrence of harmful events, thereby elevating the overall quality of health products.

Participation of Various Professionals in MvPI

The Materiovigilance Programme is inclusive, allowing clinicians, biomedical engineers, clinical engineers, hospital technology managers, pharmacists, nurses, and technicians to actively report medical device adverse events, creating a comprehensive network of safety advocates.

Significant Cases Leading to MvPI

Several incidents, such as babies being burnt due to short circuits in incubators or issues with hip implants causing blood poisoning, have necessitated the establishment of robust safety programs like MvPI.

Timeline of MvPI Implementation

Since its launch in 2015, the Materiovigilance Programme has evolved, reaching key milestones in ensuring the safety and quality of medical devices. Continuous improvements and adaptations mark its journey over the years.

Conclusion

In conclusion, the Materiovigilance Programme of India stands as a testament to the collective commitment to patient safety and healthcare quality.

The active involvement of State Regulatory Authorities, as emphasized by the DCC, is integral to the success of the program.

It is a shared responsibility to ensure that medical devices meet the highest standards, safeguarding the well-being of patients across the country.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

Investigation into Tapentadol and Pregabalin: DCC recommendation

DCC recommends SLAs to submit Adverse Drug Reaction

The Urgent Need for a Unified System in Drug Safety: DCC

DCC proposes crucial amendments for enhancing Drug Regulation

DCC recommends Transparent Packaging for Eye Drops

Drug Consultative Committee (DCC): Minutes of meetings